Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.35 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 3/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30785541 | 1.00 | TDP1 (0.41) | TDP1ALDH1A1NPSR1PGK1PTGES | |
| SCHEMBL25300547 | 0.77 | TLR7 (0.35) | PGK1EGLN1EGLN3TLR7 | |
| SCHEMBL7216099 | 0.75 | ALDH1A1 (0.55) | TDP1ALDH1A1NPSR1 | |
| SCHEMBL30681150 | 0.75 | ALDH1A1 (0.55) | TDP1ALDH1A1NPSR1 | |
| SCHEMBL30499157 | 0.73 | TLR7 (0.42) | PGK1EGLN1EGLN3TLR7 | |
| SCHEMBL25297536 | 0.73 | TLR7 (0.42) | PGK1EGLN1EGLN3TLR7 | |
| SCHEMBL2695938 | 0.70 | ALDH1A1 (0.43) | TDP1ALDH1A1NPSR1SRC | |
| SCHEMBL2698969 | 0.69 | ALDH1A1 (0.49) | TDP1ALDH1A1NPSR1SRC | |
| SCHEMBL14720762 | 0.69 | EGLN1 (0.43) | EGLN1EGLN3 | |
| SCHEMBL25250339 | 0.68 | EGLN1 (0.34) | PGK1EGLN1TLR7EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826316-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2023-11-28 | — | — | US | disclosed |
| US-11826316-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2023-11-28 | — | — | US | disclosed |
| EP-3180002-B1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2022-04-20 | — | — | EP | disclosed |
| US-20210145839-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2021-05-20 | — | — | US | disclosed |
| US-10888567-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2021-01-12 | — | — | US | disclosed |
| US-20170224701-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2017-08-10 | — | — | US | disclosed |
| US-20170224701-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2017-08-10 | — | — | US | disclosed |
| EP-3180002-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY | Auckland Uniservices Limited (NZ) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016024233-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016024233-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11826316-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | IDO1, TDO2, IDO2 | TDP1 321/4885ALDH1A1 1167/4885NPSR1 712/4885 |
| US-20170224701-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | IDO1, TDO2, IDO2 | TDP1 321/4885ALDH1A1 1167/4885NPSR1 712/4885 |
| US-20210145839-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | IDO1, TDO2, IDO2 | TDP1 321/4885ALDH1A1 1167/4885NPSR1 712/4885 |
| US-10888567-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | IDO1, TDO2, IDO2 | TDP1 321/4885ALDH1A1 1167/4885NPSR1 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.